Charleston Laboratories, Inc. Appoints Ryan Baker Executive Vice President and Chief Operating Officer. A Polished, Efficient and Dependable Executive.
Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced today the appointment of Ryan Baker, as Chief Operating Officer and Executive Vice President.
“I would be hard pressed to find the exact words that adequately express how excited I am that Ryan Baker is joining our executive management team” said Paul Bosse, President and Chief Executive Officer of Charleston. “Ryan is an original founder of the company and will be an extremely valuable asset to our executive team as he brings a combination of global finance and operational experience. I have not met many people like him that understand how to build such strong relationships that in turn drive strategic initiatives and growth. He will have day to day oversight on the company’s operational aspects as we strive to increase shareholder value through execution of milestones of our novel drug development programs.”
Prior to joining Charleston Laboratories, Inc, Mr. Baker spent 11 successful years in the Wealth Management industry with Merrill Lynch and Morgan Stanley respectively. Ryan is well versed in the pharmaceutical industry having been a co-founder of another pharmaceutical company prior to co-founding Charleston Laboratories, Inc. He has strong experience in company formation, strategic planning, budgeting and overseeing day to day operations. Mr. Baker is an Alumnus of the University of Alabama holding a degree in Finance specializing in Corporate Investment Management
“As a Founder of Charleston Laboratories, Inc., this marks as a special day in my professional career and has been a vision of both Paul and I from the inception of this company. It’s a tremendous honor to have the opportunity to work beside all the people involved with Charleston Laboratories as the Executive Vice President and Chief Operating Officer. I want to thank my family, friends and colleagues for your support in this new chapter of my life. I look forward to seeing how all the unique innovation that Charleston is spearheading positively impacts patient’s lives for many years to come”.
Charleston Laboratories, Inc is a specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting, the two most burdensome side effects related to opioid analgesics and other pain associated disease states. Charleston’s new products will address Opioid Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy Induced Nausea and Vomiting (CINV), Radiation Induced Nausea and Vomiting (RINV), and Migraine Induced Nausea and Vomiting (MINV). In addition, Charleston is developing other products without acetaminophen to reduce the potential for liver injury and formulations with abuse deterrent technologies designed to curb misuse and abuse. Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.